.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR19_EmtricitabineTenofovirAlafenamid.EmtricitabineTenofovirAlafenamid

Information

name:EmtricitabineTenofovirAlafenamideAndRilpivirine
ATC code:J05AR19
route:oral
n-compartments1

Fixed-dose combination tablet containing emtricitabine (NRTI), tenofovir alafenamide (NRTI prodrug), and rilpivirine (NNRTI); used as a complete regimen for the treatment of HIV-1 infection in adults and adolescents. The drug is currently approved for clinical use for HIV-1 management.

Pharmacokinetics

Pharmacokinetic parameters estimated for healthy adult HIV-negative volunteers after single-dose oral administration. Parameter values are approximated based on separate published PK profiles for each component, as no population PK publication exists for the fixed combination product.

References

    Revisions

    Generated at 2025-10-30T19:21:05Z by OpenModelicaOpenModelica 1.25.5 using GenerateDoc.mos